Skip to content

Interest Income at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$25.48M+3.3%
Arrowhead Research logo
Arrowhead ResearchARWR
$16.87M+75.4%
Edgewise Therapeutics, Inc. logo
Edgewise Therapeutics, Inc.EWTX
$5.1M-1.1%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$6M-14.3%
Celldex Therapeutics logo
Celldex TherapeuticsCLDX
$5.75M-35.7%
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
$7.61M+158%

Other financials

Income statement

See full
Operating income-$125.3M-2.4%
Net income-$120.9M-4.8%
EPS (diluted)-$0.73+30.5%

Balance sheet

See full
Cash & equivalents$753.1M+59.5%
Total debt$168.7M+623%
Total equity$865.1M+29.3%
Total assets$1.1B+49.8%

Cash flow

See full
Operating cash flow-$144.9M-36.9%
CapEx$221.0K-77.5%
Free cash flow-$145.1M-35.8%

Valuation

See full
Market cap$3.35B+153%

Returns & leverage

See full
Return on equity-58.9%-4.4pp
Debt / equity0.2×+0.2×
Current ratio19.9×-0.4×

Where this comes from

Reported directly by Dyne Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:InterestIncomeOther.

The official record: Dyne Therapeutics, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Dyne Therapeutics, Inc.'s interest income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Dyne Therapeutics, Inc.'s interest income?
Dyne Therapeutics, Inc. (DYN) reported interest income of $8.76M in Q1 2026.
How has Dyne Therapeutics, Inc.'s interest income changed year-over-year?
Dyne Therapeutics, Inc.'s interest income increased by 23.3% year-over-year, from $7.1M to $8.76M.
What is the long-term trend for Dyne Therapeutics, Inc.'s interest income?
Over 4 years (2021 to 2025), Dyne Therapeutics, Inc.'s interest income has grown at a 151.9% compound annual growth rate (CAGR), from $742K to $29.86M.
What does interest income mean?
Income earned from interest-bearing assets including cash deposits, money market funds, treasury securities, corporate bonds, and customer financing receivables.